Supplying Both DS and DP for Preclinical Research
A First in Korea
Kyungbo Pharmaceutical announced on December 15 that it has recently established the "ADC (Antibody-Drug Conjugate) Research Center" in Giheung-gu, Yongin-si, to produce preclinical research samples, and held an opening ceremony. The event was attended by more than 80 representatives from major ADC developers and biotech ventures.
The ADC Research Center of Kyungbo Pharmaceutical occupies approximately 2,925 square meters (exclusive area) and is equipped with a full-cycle ADC CDMO (Contract Development and Manufacturing Organization) system, ranging from the production of drug substances (DS) for preclinical studies to the nation’s first drug product (DP) manufacturing line. Production is scheduled to begin early next year.
Kim Taeyoung, CEO of Kyungbo Pharmaceutical, is giving a presentation at the opening ceremony of the ADC Research Center. Kyungbo Pharmaceutical
In particular, once the ADC manufacturing plant currently under construction in Asan, South Chungcheong Province, with an investment of about 85.5 billion won, is completed, it will be capable of producing samples for Phase 1, 2, and 3 clinical trials as well as finished ADC products starting from the end of 2027. This will establish a one-stop supply chain for ADC pharmaceuticals from preclinical research to commercialization.
Kyungbo Pharmaceutical’s strategy is to systematize its ADC platform through process development and scale-up for mass production at the ADC Research Center, as well as the manufacture of preclinical samples, and to establish a system that enables stable and efficient technology transfer to client companies.
The DS pilot production facility has been designed with a flexible structure to accommodate both single-use and multi-use systems, while the DP production facility will operate as a closed system to prevent any exposure to the outside during all processes, from vial filling to lyophilization, thereby enhancing quality and safety.
Kim Taeyoung, CEO of Kyungbo Pharmaceutical, stated, "The ADC Research Center is the only ADC CDMO facility in Korea that supplies everything from drug substances for preclinical studies to finished products. Together with the ADC manufacturing plant, we will establish a one-stop supply chain to help domestic ADC developers and biotech ventures reduce the time and cost required for producing clinical samples in China, the United States, and Europe, thereby contributing to the Korean pharmaceutical and biotech industry."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
